Biocon’s founder and managing director Kiran Mazumdar-Shaw has said the company is ready to slash the cost of recombinant human insulin it sells in low- and middle-income countries by 50% – and possibly more – to 10 cents a day.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?